Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab plus gemcitabine versus placebo plus gemcitabine in KRAS wild-type advanced pancreatic cancer
ChiCTR-IPR-15006277Phase 3Recruiting
- Sponsor
- Nanjing Bayi Hospital
- Start
- May 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nimotuzumab and gemcitabine in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Nanjing Bayi Hospital. Primary endpoint: overall survival. Started May 2014; status: recruiting.
02
Drugs
nimotuzumabgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR-IPR-15006277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006277.